Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): A 12-week open trial

Psychiatry Research

Volumn 96, Issue 2, 2000, Pages 91-98

  Bogetto, Filippo ^a   Bellino, Silvio ^a   Vaschetto, Patrizia ^a   Ziero, Simona ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Schizotypal personality disorder; Side effects; Tic disorder; Treatment outcome

Indexed keywords

FLUVOXAMINE; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPULSIVE PERSONALITY DISORDER; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; OBESITY; OBSESSION; PERSONALITY DISORDER; PRIORITY JOURNAL; SEDATION; TIC; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HUMAN; MALE; MIDDLE AGE; OBSESSIVE-COMPULSIVE DISORDER; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOTYPAL PERSONALITY DISORDER; TIC DISORDERS; TREATMENT OUTCOME;

EID: 0034735622     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(00)00203-1     Document Type: Article

References (55)

1. Effect of Axis II diagnosis on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder
2. Emergence of obsessive-compulsive symptoms during treatment with clozapine
3. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo
4. Safety of olanzapine
5. Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder
6. Olanzapine. Pharmacokinetic and pharmacodynamic profile
7. Exacerbation of obsessive-compulsive symptoms associated with clozapine
8. Is there a relationship between clozapine and obsessive-compulsive disorder? A retrospective chart review
9. Borderline and schizotypal personality disorders treated with low-dose thiothixene versus placebo
10. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo
11. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): part I. Development, use and reliability
12. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): part II. Validity
13. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder
14. Focus on olanzapine
15. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis
16. A rating scale for depression.
17. Risperidone in the treatment of affective illness and obsessive-compulsive disorder
18. Concomitant obsessive-compulsive disorder and schizotypal personality disorder
19. Special feature: pharmacotherapy in personality disorders
20. A family history study of schizophrenia-related personality disorders
21. Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness
22. Behavioral versus pharmacological treatments of obsessive-compulsive disorder: a meta-analysis
23. Risperidone, serotoninergic mechanisms, and obsessive-compulsive symptoms in schizophrenia (letter)
24. Personality disorders in obsessive-compulsive patients: a study report
25. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder
26. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder
27. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy
28. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder
29. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics
30. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder
31. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases
32. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder
33. Worsening of obsessive-compulsive symptoms following treatment with olanzapine
34. Olanzapine-induced obsessive-compulsive disorder
35. Long term follow-up of 85 patients with obsessive-compulsive disorder
36. Development of transient of obsessive-compulsive symptoms during the treatment with clozapine (letter)
37. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review
38. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in chlomipramine-treated patients with obsessive-compulsive disorder
39. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder
40. Potential of atypical antipsychotics in the treatment of nonpsychotic disorders
41. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder
42. Drug treatment of obsessive-compulsive disorder (OCD): long term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)
43. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD)
44. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder
45. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol
46. Biologic factors in schizotypal personal disorders
47. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders
48. Emergence of transint compulsive symptoms during treatment with clothiapine
49. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series
50. Novel antipsychotics: comparison of weight gain liabilities